Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RALPH J HAUKE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1578511283
CMS profile
297671
Location
OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$7,629.00

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $6,750.00 1
Food and Beverage $469.00 5
Travel and Lodging $410.00 3

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Astellas Pharma US Inc $7,342.00 5
Advanced Accelerator Applications $271.54 3
Sirtex Medical Inc $15.46 1

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RALPH J HAUKE

NPI 1578511283 · CMS profile ID 297671

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578511283?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578511283?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578511283?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1578511283?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $7,629.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Sirtex Medical Inc $15.4606/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698371209 CMS
Advanced Accelerator Applications $15.0105/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704526547 CMS
Advanced Accelerator Applications $121.1205/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 708348561 CMS
Astellas Pharma US Inc $291.0003/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655597085 CMS
Astellas Pharma US Inc $182.0003/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655597088 CMS
Astellas Pharma US Inc $23.0003/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655597091 CMS
Astellas Pharma US Inc $96.0003/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655597095 CMS
Advanced Accelerator Applications $135.4102/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 708348225 CMS
Astellas Pharma US Inc $6,750.0002/05/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655597081 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,629.00 9
PY2020 $7.49 1
PY2021 $780.92 3
PY2023 $16.02 1
PY2024 $225.23 10
PY2025 $31.33 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $609.30 2
PY2025 Principal investigator $1,167,738.55 292
PY2024 Principal investigator $1,299,594.58 212
PY2023 Principal investigator $2,735,258.21 252
PY2022 Recipient $4,157.00 1
PY2022 Principal investigator $1,567,591.67 137
PY2021 Principal investigator $2,060,900.77 213
PY2020 Recipient $705.81 1
PY2020 Principal investigator $1,867,000.72 289
PY2019 Principal investigator $1,377,455.65 354

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

138 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $773.50 12/31/2022 Non-covered Recipient Entity
ONCHEMATOLOGY WEST PC DBA NEBRASKA
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 889829071
Principal investigator 1 Merck Sharp & Dohme LLC $2,637.08 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase I,II Study of MK-3475 SCH900475 in Combination with Chemotherapy and,or Immunotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma No dispute reported 06/30/2026 940402853
Principal investigator 1 Merck Sharp & Dohme LLC $553.84 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma No dispute reported 06/30/2026 940406567
Principal investigator 1 Merck Sharp & Dohme LLC $1,184.66 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma No dispute reported 06/30/2026 940406569
Principal investigator 1 Merck Sharp & Dohme LLC $0.11 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Epacadostat or Placebo in Combination With Pembrolizumab in Subjects with Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 940406697
Principal investigator 1 Merck Sharp & Dohme LLC $24,263.76 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy KEYNOTE-564 No dispute reported 06/30/2026 940407775
Principal investigator 1 Merck Sharp & Dohme LLC $4,794.36 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy KEYNOTE-564 No dispute reported 06/30/2026 940407777
Principal investigator 1 Merck Sharp & Dohme LLC $6,825.35 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy KEYNOTE-564 No dispute reported 06/30/2026 940407815
Principal investigator 1 Merck Sharp & Dohme LLC $19,731.18 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 940407979
Principal investigator 1 Merck Sharp & Dohme LLC $242,735.89 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 940407981
Principal investigator 1 Merck Sharp & Dohme LLC $5,222.50 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 940407983
Principal investigator 1 Merck Sharp & Dohme LLC $253.65 12/31/2022 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 2, Randomized, Double-Blind Study of Pembrolizumab MK-3475 plus Epacadostat INCB024360 Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1 No dispute reported 06/30/2026 940408451
Principal investigator 1 Merck Sharp & Dohme LLC $10,339.00 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 No dispute reported 06/30/2026 940411683
Principal investigator 1 Merck Sharp & Dohme LLC $3,582.74 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 No dispute reported 06/30/2026 940411827
Principal investigator 1 Merck Sharp & Dohme LLC $13,648.67 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 1b,2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1,L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy KEYNOTE-B98 No dispute reported 06/30/2026 940413445
Principal investigator 1 Merck Sharp & Dohme LLC $44,949.51 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 1b,2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1,L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy KEYNOTE-B98 No dispute reported 06/30/2026 940413483
Principal investigator 1 Merck Sharp & Dohme LLC $4,615.56 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 1b,2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1,L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy KEYNOTE-B98 No dispute reported 06/30/2026 940413485
Principal investigator 1 Merck Sharp & Dohme LLC $15,600.06 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer KEYNOTE-B99 No dispute reported 06/30/2026 940414005
Principal investigator 1 Merck Sharp & Dohme LLC $14,284.82 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer KEYNOTE-B99 No dispute reported 06/30/2026 940414043
Principal investigator 1 Merck Sharp & Dohme LLC $4,929.48 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer KEYNOTE-B99 No dispute reported 06/30/2026 940414045
Principal investigator 1 Merck Sharp & Dohme LLC $6,624.98 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 940416959
Principal investigator 1 Merck Sharp & Dohme LLC $4,028.93 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 940416961
Principal investigator 1 Merck Sharp & Dohme LLC $26,481.56 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 plus Pembrolizumab MK- 3475 Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Nephrectomy 6482-022 No dispute reported 06/30/2026 940417085
Principal investigator 1 Merck Sharp & Dohme LLC $2,278.08 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 plus Pembrolizumab MK- 3475 Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Nephrectomy 6482-022 No dispute reported 06/30/2026 940417121
Principal investigator 1 Merck Sharp & Dohme LLC $12,813.91 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 plus Pembrolizumab MK- 3475 Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Nephrectomy 6482-022 No dispute reported 06/30/2026 940418299
Principal investigator 1 Aveo Pharmaceuticals, Inc. $3,489.75 12/22/2022 Non-covered Recipient Entity
QUALITY CANCER CARE ALLIANCE
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 950101545
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,385.45 12/22/2022 Non-covered Recipient Entity
QUALITY CANCER CARE ALLIANCE
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 950101551
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 12/22/2022 Non-covered Recipient Entity
QUALITY CANCER CARE ALLIANCE
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 950101557
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 12/22/2022 Non-covered Recipient Entity
QUALITY CANCER CARE ALLIANCE
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 950101561
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,603.80 12/22/2022 Non-covered Recipient Entity
QUALITY CANCER CARE ALLIANCE
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 950101567
Principal investigator 1 Janssen Research & Development, LLC $2,606.00 12/20/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885263661
Principal investigator 1 Janssen Research & Development, LLC $1,374.00 12/20/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885263663
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $302.00 12/15/2022 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialist
PhII 1L NSCLC Dose Safety, CoC Biomarker Evaluation - A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage No dispute reported 06/30/2026 933199144
Principal investigator 1 Janssen Research & Development, LLC $825.00 12/15/2022 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885230191
Principal investigator 1 BioNTech SE $784.00 12/14/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 963043349
Principal investigator 1 Exelixis Inc. $1,157.70 12/14/2022 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 943764995
Principal investigator 1 MACROGENICS, INC. $770.00 12/06/2022 Non-covered Recipient Entity
NEBRASKA CANCER CENTER SPECIALIST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936960541
Principal investigator 1 BioNTech SE $8,359.00 12/01/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 963043317
Principal investigator 1 BioNTech SE $1,568.00 12/01/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 963043327
Principal investigator 1 BioNTech SE $276.00 12/01/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 963043333
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $378.04 11/17/2022 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialist
Phase III 1L Melanoma non-inferiority rela+nivo FDC SubQ vs. rela+nivo FDC IV No dispute reported 06/30/2026 933193447
Principal investigator 1 Merck Sharp & Dohme LLC $168,500.00 11/11/2022 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
An Open Label, First in Human FIH, Phase 1 Trial of LVGN6051 as Single Agent and in Combination with Keytruda pembrolizumab in Advanced or Metastatic Malignancy No dispute reported 06/30/2026 940419091
Principal investigator 1 Janssen Research & Development, LLC $2,748.00 11/08/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885263659
Principal investigator 1 PFIZER INC. $1,500.00 11/08/2022 Non-covered Recipient Entity
Oncology Hematology West PC dba Nebraska Cancer Specialists
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER No dispute reported 06/30/2026 949784931
Principal investigator 1 Merck Sharp & Dohme LLC $15,750.00 11/07/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer KEYNOTE-B99 No dispute reported 06/30/2026 940414003
Principal investigator 1 MACROGENICS, INC. $1,182.05 10/19/2022 Non-covered Recipient Entity
NEBRASKA CANCER CENTER SPECIALIST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936960083
Principal investigator 1 MACROGENICS, INC. $503.00 10/19/2022 Non-covered Recipient Entity
NEBRASKA CANCER CENTER SPECIALIST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936960089
Principal investigator 1 MACROGENICS, INC. $829.95 10/19/2022 Non-covered Recipient Entity
NEBRASKA CANCER CENTER SPECIALIST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936960093
Principal investigator 1 BioNTech SE $4,596.80 10/18/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 963043341
Principal investigator 1 Eisai Inc. $956.00 10/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 926003043
Principal investigator 1 Janssen Research & Development, LLC $825.00 10/15/2022 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885230189
Principal investigator 1 Janssen Research & Development, LLC $824.00 10/15/2022 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885230209
Principal investigator 1 Exelixis Inc. $2,271.20 10/14/2022 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 943764411
Recipient Novartis Pharmaceuticals Corporation $4,157.00 10/01/2022 Covered Recipient Physician PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH No dispute reported 06/30/2026 909430601
Principal investigator 1 Merck Sharp & Dohme LLC $91,000.00 09/27/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P.C. DBA NEBRASKA CANCER SPECIALISTS
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 940419061
Principal investigator 1 BioNTech SE $250.00 09/23/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 963043365
Principal investigator 1 BioNTech SE $8,635.00 09/23/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 963043373
Principal investigator 1 Gilead Sciences, Inc. $11,700.00 09/21/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 920353435
Principal investigator 1 Janssen Research & Development, LLC $824.00 09/15/2022 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885230187
Principal investigator 1 Exelixis Inc. $1,135.60 09/14/2022 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 943762793
Principal investigator 1 Merck Sharp & Dohme LLC $25,381.91 09/12/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 1b,2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1,L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy KEYNOTE-B98 No dispute reported 06/30/2026 940413301
Principal investigator 1 BioNTech SE $8,624.00 09/07/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 963043357
Principal investigator 1 Janssen Research & Development, LLC $5,496.00 09/06/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885263657
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $9,972.36 08/24/2022 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors No dispute reported 06/30/2026 890234751
Principal investigator 1 Janssen Research & Development, LLC $825.00 08/15/2022 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885230227
Principal investigator 1 Exelixis Inc. $5,678.00 08/12/2022 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 943762707
Principal investigator 1 BioNTech SE $750.00 08/11/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 963043387
Principal investigator 1 BioNTech SE $1,500.00 08/11/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 963043395
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $15,500.00 08/02/2022 Non-covered Recipient Entity
Hematology / Oncology West Pc
Phase I IIA Nivo Combo Study No dispute reported 06/30/2026 933190807
Principal investigator 1 BioNTech SE $12,641.20 07/27/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 963043379
Principal investigator 1 Eisai Inc. $956.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 926003041
Principal investigator 1 Janssen Research & Development, LLC $1,103.00 07/15/2022 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885230203
Principal investigator 1 Janssen Research & Development, LLC $825.00 07/15/2022 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885230225
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,250.00 07/14/2022 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 933186593
Principal investigator 1 Aveo Pharmaceuticals, Inc. $20,500.00 07/11/2022 Non-covered Recipient Entity
QUALITY CANCER CARE ALLIANCE
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 950101523
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,000.00 07/11/2022 Non-covered Recipient Entity
QUALITY CANCER CARE ALLIANCE
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 950101535
Principal investigator 1 Aveo Pharmaceuticals, Inc. $900.00 07/11/2022 Non-covered Recipient Entity
QUALITY CANCER CARE ALLIANCE
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 950101539
Principal investigator 1 ARRAY BIOPHARMA INC $500.00 06/28/2022 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
AN OPENLABEL PHASE 1 STUDY TO EVALUATE DRUGDRUG INTERACTIONS OF AGENTS COADMINISTERED WITH ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF V600MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949706255
Principal investigator 1 ARRAY BIOPHARMA INC $1,000.00 06/23/2022 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
AN OPENLABEL PHASE 1 STUDY TO EVALUATE DRUGDRUG INTERACTIONS OF AGENTS COADMINISTERED WITH ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF V600MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949706239
Principal investigator 1 ARRAY BIOPHARMA INC $275.00 06/23/2022 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
AN OPENLABEL PHASE 1 STUDY TO EVALUATE DRUGDRUG INTERACTIONS OF AGENTS COADMINISTERED WITH ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF V600MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949706871
Principal investigator 1 ARRAY BIOPHARMA INC $1,000.00 06/23/2022 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
AN OPENLABEL PHASE 1 STUDY TO EVALUATE DRUGDRUG INTERACTIONS OF AGENTS COADMINISTERED WITH ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF V600MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949706905
Principal investigator 1 Gilead Sciences, Inc. $1,250.00 06/22/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 920353433
Principal investigator 1 ARRAY BIOPHARMA INC $1,075.00 06/21/2022 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
AN OPENLABEL PHASE 1 STUDY TO EVALUATE DRUGDRUG INTERACTIONS OF AGENTS COADMINISTERED WITH ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF V600MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949706223
Principal investigator 1 ARRAY BIOPHARMA INC $625.00 06/21/2022 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
AN OPENLABEL PHASE 1 STUDY TO EVALUATE DRUGDRUG INTERACTIONS OF AGENTS COADMINISTERED WITH ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF V600MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949706887
Principal investigator 1 ARRAY BIOPHARMA INC $1,100.00 06/21/2022 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
AN OPENLABEL PHASE 1 STUDY TO EVALUATE DRUGDRUG INTERACTIONS OF AGENTS COADMINISTERED WITH ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF V600MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949707685
Principal investigator 1 Janssen Research & Development, LLC $824.00 06/15/2022 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885230219
Principal investigator 1 Janssen Research & Development, LLC $1,298.00 06/07/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885263655
Principal investigator 1 BioNTech SE $8,635.00 05/20/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 963043449
Principal investigator 1 Janssen Research & Development, LLC $4,122.00 05/16/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885263653
Principal investigator 1 Janssen Research & Development, LLC $1,103.00 05/15/2022 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885230205
Principal investigator 1 Janssen Research & Development, LLC $824.00 05/15/2022 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885230217
Principal investigator 1 MACROGENICS, INC. $665.00 05/10/2022 Non-covered Recipient Entity
NEBRASKA CANCER CENTER SPECIALIST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936957513
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,500.00 05/06/2022 Non-covered Recipient Entity
Hematology / Oncology West Pc
Phase III Adjuvant Melanoma Stage II B C Opdivo Mono No dispute reported 06/30/2026 933194401
Principal investigator 1 Merck Sharp & Dohme LLC $2,250.00 04/20/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 940416957
Principal investigator 1 Eisai Inc. $956.00 04/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 926003039
Principal investigator 1 Incyte Corporation $1,063.00 04/15/2022 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations No dispute reported 06/30/2026 905228857
Principal investigator 1 Janssen Research & Development, LLC $825.00 04/15/2022 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885230193
Principal investigator 1 Janssen Research & Development, LLC $2,747.00 04/15/2022 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885230213
Principal investigator 1 Janssen Research & Development, LLC $824.00 04/15/2022 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885230215
Principal investigator 1 Exelixis Inc. $18,500.00 04/08/2022 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760095
Principal investigator 1 Merck Sharp & Dohme LLC $16,000.00 04/08/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 plus Pembrolizumab MK- 3475 Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Nephrectomy 6482-022 No dispute reported 06/30/2026 940418297
Principal investigator 1 Janssen Research & Development, LLC $1,374.00 04/05/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885263651
Principal investigator 1 Exelixis Inc. $1,135.60 03/23/2022 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 943767057
Principal investigator 1 AstraZeneca AB $68,564.60 03/17/2022 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase I, Open-label, Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination with Novel Agents in Patients with Advanced Prostate Cancer No dispute reported 06/30/2026 914603587
Principal investigator 1 Janssen Research & Development, LLC $825.00 03/15/2022 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885230199
Principal investigator 1 Janssen Research & Development, LLC $825.00 03/15/2022 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885230201
Principal investigator 1 Astellas Pharma Global Development $2,250.00 03/10/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Maligt Solid Tumors (EV-202) No dispute reported 06/30/2026 935428425
Principal investigator 1 Astellas Pharma Global Development $10,100.80 03/07/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Maligt Solid Tumors (EV-202) No dispute reported 06/30/2026 935428441
Principal investigator 1 BioNTech SE $8,359.00 02/23/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 963043411
Principal investigator 1 BioNTech SE $276.00 02/23/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 963043441
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $1,000.00 02/23/2022 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors No dispute reported 06/30/2026 890234749
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $42,766.00 02/15/2022 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
Ph III MIBC Neoadjuvant 1L Bladder IDO Nivo chemo No dispute reported 06/30/2026 933190093
Principal investigator 1 Janssen Research & Development, LLC $1,103.00 02/15/2022 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885230211
Principal investigator 1 Janssen Research & Development, LLC $824.00 02/15/2022 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885230221
Principal investigator 1 Janssen Research & Development, LLC $824.00 02/15/2022 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885230223
Principal investigator 1 Exelixis Inc. $1,135.60 02/14/2022 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 943766483
Principal investigator 1 BioNTech SE $784.00 02/10/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 963043433
Principal investigator 1 PFIZER INC. $2,500.00 02/04/2022 Non-covered Recipient Entity
Oncology Hematology West PC dba Nebraska Cancer Specialists
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER No dispute reported 06/30/2026 949784905
Principal investigator 1 Exelixis Inc. $1,135.60 02/02/2022 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 943766613
Principal investigator 1 Exelixis Inc. $1,135.60 02/02/2022 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 943766651
Principal investigator 1 Exelixis Inc. $2,271.20 02/02/2022 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 943766683
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $132.15 01/26/2022 Non-covered Recipient Entity
Nebraska Cancer Specialists
Ph III MIBC Neoadjuvant 1L Bladder IDO + Nivo + chemo No dispute reported 06/30/2026 933190013
Principal investigator 1 BioNTech SE $784.00 01/25/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 963043403
Principal investigator 1 Astellas Pharma Global Development $8,811.88 01/20/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Maligt Solid Tumors (EV-202) No dispute reported 06/30/2026 935429337
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,100.00 01/18/2022 Non-covered Recipient Entity
Us Oncology Res Llc
Ph IIB Prostate Combos PARP Enza Chemo No dispute reported 06/30/2026 933189565
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $48,587.00 01/18/2022 Non-covered Recipient Entity
Us Oncology Res Llc
Ph III MIBC Neoadjuvant 1L Bladder IDO Nivo chemo No dispute reported 06/30/2026 933190117
Principal investigator 1 Eisai Inc. $956.00 01/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 926003037
Principal investigator 1 Incyte Corporation $1,063.00 01/15/2022 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations No dispute reported 06/30/2026 905228855
Principal investigator 1 Janssen Research & Development, LLC $825.00 01/15/2022 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885230195
Principal investigator 1 Janssen Research & Development, LLC $825.00 01/15/2022 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885230197
Principal investigator 1 Janssen Research & Development, LLC $1,103.00 01/15/2022 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 885230207
Principal investigator 1 Novartis Pharmaceuticals Corporation $146.52 01/15/2022 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE III STUDY COMPARING THE COMBINATION OF PDR001 DABRAFENIB AND TRAMETINIB VERSUS PLACEBO DABRAFENIB AND TRAMETINIB IN PREVIOUSLY UNTREATED PATIENTS WITH UNRESECTABLE OR METASTATIC BRAF V600 MUTANT MELANOMA No dispute reported 06/30/2026 909409353
Principal investigator 1 Novartis Pharmaceuticals Corporation $11.92 01/15/2022 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
TWO ARM RANDOMIZED PHASE 3 STUDY IN HIGH RISK NSCLC COMPARING CANAKINUMAB VS PLACEBO IN ADJUVANT SETTING No dispute reported 06/30/2026 909409361
Principal investigator 1 Novartis Pharmaceuticals Corporation $285,841.19 01/11/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST NEBRASKA CANCER SPECIALIST
AN OPEN-LABEL, RANDOMIZED, PHASE III STUDY COMPARING 177LU-PSMA-617 IN COMBINATION WITH STANDARD OF CARE, VERSUS STANDARD OF CARE ALONE, IN ADULT MALE PATIENTS WITH METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC) No dispute reported 06/30/2026 909411447
Principal investigator 1 Novartis Pharmaceuticals Corporation $57,354.67 01/11/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST NEBRASKA CANCER SPECIALIST
PSMAFORE: A PHASE III, OPEN-LABEL, MULTI-CENTER, RANDOMIZED STUDY COMPARING 177LU-PSMA-617 VS. A CHANGE OF ANDROGEN RECEPTOR-DIRECTED THERAPY IN THE TREATMENT OF TAXANE NAIVE MEN WITH PROGRESSIVE METASTATIC CASTRATE RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 910071613
Principal investigator 1 BioNTech SE $784.00 01/07/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 963043419
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,642.00 01/07/2022 Non-covered Recipient Entity
Us Oncology Res Llc
An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CheckMate 627) No dispute reported 06/30/2026 933187717
Principal investigator 1 BioNTech SE $459.00 01/01/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 963043426